Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

"Switching to intravitreal aflibercept 8mg in patients previously treated with faricimab or aflibercept 2mg.~The dosing schedule is as follows.~1. A single dose of 8mg aflibercept was administered to all patients~2. After treatment 1, follow-up observations were conducted at the same intervals as previous treatments. If complete fluid resolution (no evidence of SRF or IRF) is observed, an additional dose of 8mg aflibercept is administered, extending the dosing intervals by two weeks each time.~3. Up to three doses of 8mg aflibercept can be administered.~4. If, after the administration of 8mg aflibercept, follow-up observations reveal remaining SRF or IRF, the study concludes without additional dosing."